About
Novel medicines that target the cGAS-STING pathway
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
64
By Phase
PHASE1: 1PHASE2: 2PHASE1/PHASE2: 1
By Status
TERMINATED: 2ACTIVE_NOT_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06026254Lead Sponsor
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
PHASE1Active, not recruiting
2 participants
Started: Sep 15, 2023 · Completed: Sep 30, 2025
NCT05846659Lead Sponsor
Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies
PHASE2Terminated
16 participants
Started: Jul 7, 2023 · Completed: Nov 20, 2024
NCT05846646Lead Sponsor
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
PHASE2Terminated
6 participants
Started: Jun 28, 2023 · Completed: Sep 16, 2024
NCT04020185Lead Sponsor
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
PHASE1/PHASE2Completed
40 participants
Started: Sep 23, 2019 · Completed: Sep 15, 2023
Funding History (1)
D
Dec 5, 2022
Locations (1)
Headquarters
Dallas, TX, United States
Map
Loading map...